Embolization of hepatocellular carcinoma with drug-eluting beads(CalliSpheres): Doxorubicin tissue concentration and distribution in patient liver explants or liver resections

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIC-16010201

Enrollment

Unknown

Registered

2016-12-21

Start date

2016-08-20

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

DEB-TACE group:Doxorubicin-eluting beads (CalliSpheres) TACE

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Aged from 18 to 75, male or female; 2) Histopathological or clinical diagnosis of hepatocellular carcinoma( Reference for the Standard Specification for diagnosis and treatment of primary liver cancer in 2011); 3) The long diameter of the measurable lesion is less than 3cm; 4) Expected survival time is longer than three months; 5) Patients with liver transplantation indication or who plan for liver transplantation or liver tumor resection; 6) Patients who are suitable for and agree to accept DEB-TACE before liver transplantation or liver tumor resection; 7) Patients who are consent to donate liver tissue for scientific research after liver transplantation or liver tumor resection; 8) Pregnancy test for women of childbearing age must be negative.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Histological evaluation;Controlled release time of chemotherapeutic drugs in tumor tissue;	—

Countries

China

Contacts

Public ContactJunhui Sun

The First Hospital Affiliated to Zhejiang University

sunjh121@163.com+86 13575725162

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026